UK registered clinicians
100% discretion on all consultations
High quality Professional advice and support
Best-priced GLP-1 in the UK

January, 14 2026

Wegovy 7.2 mg Approved in the UK

image

The UK has officially approved Wegovy (semaglutide) 7.2 mg, representing one of the most important developments in medical weight-management since GLP-1 therapies were first introduced.

At Mederoo Health, we see this as a pivotal step forward for patients who have worked through standard dosing but have reached a weight-loss plateau on 2.4 mg, as well as for clinicians seeking stronger, evidence-based options within a familiar and well-studied medication class.

Most importantly, this approval reinforces a core principle we believe in strongly:

Obesity is a chronic, biological condition — not a lack of willpower.

What Is Wegovy 7.2 mg?

Wegovy 7.2 mg is a higher-strength formulation of semaglutide, a GLP-1 receptor agonist that supports weight loss by acting on multiple physiological pathways:

  • Increasing satiety

  • Reducing hunger signalling

  • Slowing gastric emptying

  • Modulating reward pathways linked to food intake

  • Reducing overall calorie consumption

The mechanism of action is unchanged — the difference lies in dose intensity, allowing for enhanced appetite and metabolic control in patients who need it.

What Does the Evidence Show?

Approval of the 7.2 mg dose is supported by strong clinical evidence from the STEP UP trial, which followed over 1,400 adults with obesity for 72 weeks.

Key outcomes:

  • Average weight loss: 20.7% at 7.2 mg

  • 17.5% at 2.4 mg

  • 2.4% with placebo

Clinically meaningful results

  • ⭐ 33.2% of participants lost ≥25% of body weight

  • ⭐ This level of reduction approaches outcomes typically associated with bariatric surgery

  • ⭐ In selected trial cohorts, 7.2 mg matched or outperformed weight-loss results seen with tirzepatide, a medication often considered the most potent medical option available

Safety profile

Importantly, tolerability remained consistent with lower doses of semaglutide:

  • Gastrointestinal effects (nausea, diarrhoea, constipation, reflux) occurred at similar rates

  • Side effects were predictable, dose-related, and tended to improve over time

Because the formulation and mechanism remain unchanged, and safety thresholds were met, the MHRA authorised 7.2 mg as an extension of the existing Wegovy licence, with strict requirements for:

  • Gradual dose escalation

  • Careful patient selection

  • Ongoing clinical monitoring

Who Is Wegovy 7.2 mg For?

Wegovy 7.2 mg is not a starting dose.

It may be appropriate for patients who:

  • Have completed the full titration pathway up to 2.4 mg

  • Are tolerating 2.4 mg well

  • Continue to experience significant hunger or cravings

  • Have reached a sustained weight-loss plateau

Because this is a higher dose, some patients may notice increased gastrointestinal sensitivity during the initial weeks. At Mederoo Health, we emphasise:

  • Supportive nutrition strategies

  • Adequate hydration

  • Smaller, protein-focused meals

These measures significantly improve tolerability and long-term adherence.

Is Wegovy 7.2 mg Available Through Mederoo Health?

Yes. Following UK approval, Wegovy 7.2 mg is now available via regulated private prescribing.

Patients will require:

  • A full clinical assessment

  • Review of side-effects and response to previous doses

  • Confirmation of tolerance at 2.4 mg

  • A personalised escalation and monitoring plan

Our approach prioritises safety, sustainability, and long-term metabolic health — not rapid or unsafe dose escalation.

Why This Approval Matters

The approval of Wegovy 7.2 mg reinforces three key truths:

1. Obesity is biological — not behavioural

Many patients require stronger hormonal signalling support to achieve and maintain meaningful weight loss.

2. Medical weight-loss treatment is evolving rapidly

With 7.2 mg now approved, the therapeutic gap between semaglutide and newer dual-agonist medications has narrowed significantly.

3. Personalised care matters

Not every patient responds the same way — higher-dose options allow treatment to be tailored, rather than forcing patients to “fail” standard doses.

If you’re currently using Wegovy and feel you’ve reached a plateau — or want to explore whether higher-dose treatment is clinically appropriate — Mederoo Health can guide you through a safe, evidence-based assessment.

Because effective weight loss isn’t about trying harder — it’s about treating the biology properly.